Cybrexa appoints new chief medical officer

15 December 2022

Privately held US clinical-stage biotech Cybrexa Therapeutics today announced the appointment of Michael Needle as chief medical officer.

A board-certified hematologist/oncologist, Dr Needle will be responsible for overseeing and strategizing the continued development of Cybrexa’s advancing pipeline. The company recently presented positive findings from its first-in-human study of lead candidate, CBX-12 (alphalex-exatecan) at the annual EORTC-NCI-AACR (ENA) Symposium in October 2022.

Dr Needle brings more than 20 years of industry experience in clinical, business development, regulatory, and safety. Prior to joining Cybrexa, he served as CMO for Aveo Oncology, Array BioPharma, Multiple Myeloma Research Foundation and Consortium, and was also vice president, pediatric strategy at Celgene. He holds a Doctor of Medicine from State University of New York, Downstate Medical Center, and a Bachelor of Arts in physics from Binghamton University.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK